Compare Las Vegas Sands Corp. (LVS) vs Philip Morris International Inc. (PM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Las Vegas Sands Corp. vs Philip Morris International Inc. — how do they compare? Las Vegas Sands Corp. trades at $36.38 (market cap $23.19B), while Philip Morris International Inc. trades at $199.9 (market cap $300.33B). The key difference: Philip Morris International Inc. is far larger — about 13× Las Vegas Sands Corp.'s market cap, and Las Vegas Sands Corp. pays the higher dividend (3.35%). Which is the better fit depends on your goals — on Pluang, investors hold Las Vegas Sands Corp. for 72 Days and Philip Morris International Inc. for 85 Days on average.
| LVS | PM | |
|---|---|---|
Market Cap | $23.19B | $300.33B |
Volume | 4,822,073 | 3,935,700 |
Sector | Consumer Cyclical | Consumer Staples |
52-Week High | $69.49 | $200.50 |
52-Week Low | $35.81 | $144.33 |
Typical Hold Time | 72 Days | 85 Days |
Enterprise Value | $35.08B | $343.44B |
Dividend Yield | 3.35% | 3.32% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
LVS trades at $36.10, down 0.58% on the day, with a bearish technical signal despite recent earnings beats. The company shows strong revenue growth from $13.02B in 2025 to projected $13.7B in 2026, with consistent profitability margins around 12.5%. Recent news highlights Sands China's community initiatives and environmental certifications, supporting long-term positioning in Macao's tourism market.
Wall Street maintains strong bullish sentiment with 59% buy ratings and a $59.78 price target representing 66% upside potential. Key risks include high debt levels (73.15% debt-to-asset ratio) and Macao regulatory exposure. The current valuation at 13.88 P/E appears attractive relative to growth prospects, though technical indicators suggest near-term pressure.
Philip Morris International (PM) trades at $200.5, up 5.3% over 24 hours, with a bullish technical signal and strong earnings beats in Q1 and Q2 2026. The company shows robust fundamentals with 2025 revenue of $40.65B and net income of $11.35B, supported by a 67.48% gross margin. Recent news highlights expansion of smoke-free products like ZYN and IQOS, now over 40% of revenue, driving growth amid industry shifts.
Outlook is positive with analyst consensus at Buy (68%) and a $212.17 price target, though elevated P/E of 26.46 and regulatory risks in tobacco remain concerns. Earnings growth and smoke-free product adoption are key catalysts, but investors should monitor debt levels and competitive pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Las Vegas Sands Corp.
Las Vegas Sands is the world's largest operator of fully integrated resorts, featuring casino, hotel, entertainment, food and beverage, retail, and convention center operations. The company owns the Venetian Macao, Sands Macao, Londoner, Four Seasons Hotel Macao, and Parisian in Macao, and the Marina Bay Sands resort in Singapore. Its Venetian and Palazzo Las Vegas in the U.S. asets were sold to Apollo and VICI for $6.25 billion in 2022. We expect Sands to open a fourth tower in Singapore in 2026. After the sale of its Vegas assets, the company will generate all its EBITDA from Asia, with its casino operations generating the majority of sales.
Read more on LVS →About Philip Morris International Inc.
Philip Morris International is an international tobacco company with a product portfolio primarily consisting of cigarettes and reduced-risk products, including heat-not-burn, vapor and oral nicotine products, which are sold in markets outside the United States. The company diversified away from nicotine products with the acquisition of Vectura, a provider of innovative inhaled drug delivery solutions, in 2021.
Read more on PM →
